IMSI, PICSI & MACS in IVF: Sperm Selection Evidence Review
Key Takeaways
Across rigorous clinical trials and Cochrane systematic reviews, laboratory sperm-selection add-ons (IMSI, PICSI, and MACS) do not show a reliable increase in live birth rates compared with standard ICSI. PICSI has shown a possible miscarriage-reduction signal as a secondary outcome, but its clinical importance remains uncertain. ESHRE and HFEA therefore do not support routine use; AUA/ASRM guidance limits routine sperm DNA-fragmentation testing in the initial evaluation.
Key evidence: ESHRE Good Practice Recommendations on Add-ons in ART (2023) The HABSelect RCT: PICSI vs Conventional ICSI (Lancet 2019) HFEA Treatment Add-ons: PICSI Traffic-Light Review
Sperm Selection Techniques Explained by Dr. Senai Aksoy
This video includes English and Arabic voiceovers and subtitles. You can choose the audio track and subtitles in the YouTube player settings.
What are IMSI, PICSI, and MACS?
IMSI, PICSI, and MACS are laboratory techniques that add visual, biochemical, or magnetic selection steps when sperm are prepared for Intracytoplasmic Sperm Injection (ICSI). Their laboratory rationale is different from their proven clinical value.
In standard ICSI, an embryologist evaluates motile sperm under an inverted microscope at 200× to 400× magnification, selecting a single sperm based on progressive motility and normal overall shape. The three add-on techniques introduce alternative sorting mechanisms:
- IMSI (Intracytoplasmic Morphologically Selected Sperm Injection): Uses high-powered digital optics (up to 6,000–10,000× magnification) to examine the internal organelle structure of the sperm head in real time. Its goal is to deselect sperm with large nuclear vacuoles (LNVs), which correlate with chromatin defects.
- PICSI (Physiological Intracytoplasmic Sperm Injection): Selects sperm that bind to hyaluronic acid (HA), a component of the oocyte’s cumulus matrix. This is a laboratory marker of sperm selection; binding has been associated with lower DNA-fragmentation measures, but that association does not establish a live-birth benefit.
- MACS (Magnetic-Activated Cell Sorting): Uses magnetic particles conjugated with Annexin V to retain sperm with externalized phosphatidylserine, a marker associated with apoptosis. The remaining fraction may show improved laboratory measures of membrane or DNA integrity, but clinical benefit remains unproven.
The clinical evidence: what the trials show
The biological rationale behind each technique is plausible, but a laboratory difference does not automatically translate into a patient benefit. The available randomized evidence has not demonstrated a reliable live-birth advantage over standard ICSI.
1. IMSI Evidence: High Magnification, Unchanged Birth Rates
Examining sperm at 10,000× magnification can sound appealing. However, clinical outcomes have not supported routine adoption:
- A 2020 Cochrane review included 13 RCTs involving 2,775 couples. For live birth, the pooled estimate came from 5 studies involving 929 couples and remained uncertain: RR 1.11, 95% CI 0.89–1.39.
- ESHRE notes that IMSI can be time-consuming and affect laboratory workflow. It does not establish that this translates into a clinical disadvantage.
2. PICSI Evidence: No Live Birth Gain, but a Miscarriage Reduction Signal
The landmark UK HABSelect trial (Miller et al., The Lancet 2019), which randomized 2,772 couples across 16 NHS fertility clinics, showed:
- Primary outcome: No statistically significant difference in term live birth rates (27.4% in the PICSI group vs 25.2% in standard ICSI; OR 1.12, 95% CI 0.95–1.34).
- Secondary outcome: A statistically significant reduction in clinical miscarriage rates (4.3% with PICSI vs 7.0% with standard ICSI; OR 0.61, 95% CI 0.43–0.84).
- A 2019 Cochrane review (Lepine et al.) confirmed this reduction in miscarriage (RR 0.61, 95% CI 0.45–0.83), although the overall certainty of evidence was graded as low.
3. MACS Evidence: Lacking Large-Scale RCT Validation
- A 2019 Cochrane review found very low-certainty evidence for MACS, with uncertain effects on live birth in one RCT involving 62 couples (RR 1.95, 95% CI 0.89–4.29).
- The largest retrospective clinical registry study from IVIRMA (Pacheco et al., 2021), evaluating 48,586 autologous ICSI cycles, found no significant difference in clinical pregnancy or live birth rates between MACS and standard ICSI.
Professional guidelines and regulatory positions
Because these add-ons increase laboratory workload and treatment costs without verified improvements in live birth rates, major international bodies advise strict caution:
- ESHRE 2023 Add-ons Guidelines: The European Society of Human Reproduction and Embryology explicitly advises that IMSI, PICSI, and MACS are not recommended for routine clinical use in ART due to insufficient evidence supporting live birth efficacy.
- HFEA (UK) Traffic-Light Rating: The British regulator rates PICSI as “black” (no proven effect on term live birth) and IMSI as “grey” (insufficient evidence). The HFEA emphasizes that unproven add-ons should not be sold as routine standard of care.
- ASRM/AUA Male Infertility Guideline (amended 2024): Does not recommend sperm DNA-fragmentation analysis in the initial evaluation; it supports considering SDF assessment in couples with recurrent pregnancy loss.
When might these techniques be discussed?
These situations may prompt a discussion, but none of them proves that an add-on will improve live birth or miscarriage outcomes.
Persistently elevated sperm DNA fragmentation
If sperm DNA fragmentation remains elevated on repeat testing after modifiable causes have been addressed, the result may prompt a discussion of laboratory options. Cut-offs vary by assay, and current evidence does not establish that PICSI or MACS improves embryo quality or live birth for this subgroup.
Recurrent pregnancy loss with no clear explanation
Sperm DNA-fragmentation assessment may be considered in recurrent pregnancy loss. PICSI showed a possible miscarriage-reduction signal in HABSelect, but this was a secondary outcome and does not establish PICSI as a treatment for recurrent pregnancy loss.
Severe Teratozoospermia with Prior ICSI Fertilization Failure
In rare cases where severe structural sperm abnormalities coincide with previous unexplained fertilization failure despite adequate oocyte factors, some clinicians may discuss IMSI as a laboratory option. Its theoretical selection benefit has not translated into a proven live-birth advantage.
Dr. Aksoy’s clinical perspective
Dr. Aksoy’s Approach: Evidence-Based Selection vs Add-on Hype
“I never prescribe IMSI, PICSI, or MACS as routine treatment packages. An elevated DNA fragmentation result, recurrent pregnancy loss, or severe teratozoospermia is not an automatic green light for laboratory add-ons.
My first priority is always to determine whether sperm DNA damage is truly persistently elevated and to treat the underlying root causes: clinical varicoceles, smoking, scrotal heat exposure, medications, subclinical infections, and lifestyle factors. In recurrent miscarriage, we must equally investigate maternal, uterine, and chromosomal factors before focusing solely on the sperm dish.
In carefully selected couples, I may discuss PICSI as an option, while explaining that its effect on miscarriage remains uncertain and its live-birth benefit is unproven. MACS is reserved for very narrow research or registry protocols. IMSI is considered only when severe teratozoospermia is accompanied by prior unexplained fertilization failure in standard ICSI—never solely because morphology is 0%.
To patients asking to try every possible add-on, my advice is clear: a failed cycle does not mean we missed a secret laboratory trick. Stacking multiple weak-evidence add-ons multiplies costs and clouds our clinical judgment. We discuss each tool’s evidence, costs, and the valid option of performing standard, high-quality ICSI without add-ons—and we only make a change when it is medically justified.”
— Dr. Senai Aksoy
Related Reading
- Strategies to Improve Sperm Quality Naturally and Medically
- Varicocele Repair vs IVF/ICSI: When to Treat the Cause First
- Micro-TESE for Azoospermia: Understanding Surgical Retrieval
FAQ
Do IMSI, PICSI, or MACS improve pregnancy or live-birth rates?
No reliable improvement has been demonstrated for either pregnancy or live birth compared with standard ICSI.
Does PICSI reduce the risk of miscarriage?
It may; HABSelect found an approximately 39% relative reduction as a secondary outcome. Because the trial was not designed primarily to test miscarriage, and overall certainty is low, this is not an established treatment benefit and it did not increase total live births.
Why does the UK HFEA rate PICSI as “black”?
The HFEA rates PICSI as black because its primary objective in trials—improving full-term live births—showed no significant difference compared with standard ICSI.
Is IMSI superior to standard ICSI for severe male factor infertility?
IMSI allows detailed examination of sperm head vacuoles at up to 10,000× magnification. While this aids morphological sorting, clinical trials show no proven advantage in live birth outcomes over standard ICSI.
Are advanced sperm selection techniques safe?
There is no clear signal of increased congenital anomalies in the available evidence, but prospective safety data remain limited. ESHRE reports no safety data for IMSI and MACS, while HFEA says IMSI has no additional known risks beyond those associated with ICSI.
Sources
- Teixeira DM, Barbosa MAP, Cecchino GN, et al. Intracytoplasmic morphologically selected sperm injection (IMSI) for assisted reproduction. Cochrane Database Syst Rev 2020;2(2):CD008167.
- Miller D, Pavitt S, Sharma V, et al. Physiological intracytoplasmic sperm injection (PICSI) versus conventional intracytoplasmic sperm injection (ICSI) in couples undergoing assisted reproductive technology: the HABSelect RCT. The Lancet 2019;393(10170):416–427.
- Lepine S, McDowell G, Searle R, et al. Advanced sperm selection techniques for assisted reproduction. Cochrane Database Syst Rev 2019;2019(7):CD010461.
- Pacheco A, Cruz M, Iglesias C, et al. Magnetic-activated cell sorting (MACS) does not improve clinical outcomes in autologous-oocyte ICSI cycles: a retrospective study of 48,586 cycles. Biology (Basel) 2021;10(5):444.
- ESHRE Working Group on Add-ons in ART. Good practice recommendations on add-ons in reproductive medicine. Hum Reprod 2023;38(11):2062–2080.
- Human Fertilisation and Embryology Authority (HFEA). Physiological intracytoplasmic sperm injection (PICSI) traffic-light rating. Current patient guidance, accessed 21 August 2026.
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.